TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy.
Saved in:
| Title: | TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy. |
|---|---|
| Authors: | McNerney, K. O.1, Karageorgos, S.2, Ferry, G. M.2, Wolpaw, A. J.1,3, Burudpakdee, C.2, Khurana, P.2, Toland, C. N.2, Vemu, R.1, Vu, A.1, Hogarty, M. D.1,4, Bassiri, H.2,4 bassiri@chop.edu |
| Source: | OncoImmunology. 2022, Vol. 11 Issue 1, p1-13. 13p. |
| Database: | Academic Search Ultimate |
| ISSN: | 21624011 |
|---|---|
| DOI: | 10.1080/2162402X.2022.2075204 |
